You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC; Mesothelioma; Pemetrexed; Safety assessment; PMS

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Mesothelioma, Thymoma Trial in Breda, Dordrecht (Folinic acid)

Recruiting
  • NSCLC
  • +2 more
  • Folinic acid
  • Breda, Noord Brabant, Netherlands
  • +1 more
Aug 17, 2023

Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma Trial in Augusta (Cabozantinib,

Recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Augusta, Georgia
    Augusta University Georgia Cancer Center
Mar 6, 2022

Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

Completed
  • Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy
  • pemetrexed-related hematological toxicity
  • Reims, France
    Chu Reims
Feb 11, 2022

Alvopem® (Pemetrexed) Safety Assessment

Completed
  • Non Small Cell Lung Cancer
  • Malignant Pleural Mesothelioma
  • (no location specified)
Apr 10, 2021

Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC Trial in Rozzano, Siena, Glasgow (IOA-244, Avelumab Injection,

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • Rozzano, Milan, Italy
  • +2 more
May 13, 2022

Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,

Not yet recruiting
  • Malignant Pleural Mesothelioma
  • Dendritic cell vaccination
  • +2 more
  • Edegem, Antwerp, Belgium
  • +2 more
Feb 28, 2023

Pleural Mesothelioma Trial in Italy (Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab)

Not yet recruiting
  • Pleural Mesothelioma
  • Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
  • Rozzano, MI, Italy
  • +5 more
Nov 30, 2023

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • 's-Hertogenbosch, Netherlands
  • +4 more
Sep 9, 2022

NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

Not yet recruiting
  • NSCLC Associated With Leptomeningeal Metastases
  • Tislelizumab, pemetrexed
  • (no location specified)
Nov 21, 2023

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Terminated
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • 's-Hertogenbosch, Netherlands
  • +4 more
May 9, 2022

Non Small Cell Lung Cancer, Mesothelioma Trial in Netherlands (Pemetrexed)

Completed
  • Non Small Cell Lung Cancer
  • Mesothelioma
  • 's-Hertogenbosch, Netherlands
  • +4 more
May 9, 2022

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
    • (no location specified)
    Sep 13, 2023

    NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • (no location specified)
    Mar 27, 2023

    Peritoneal Malignant Mesothelioma Trial in United States (biological, drug, procedure)

    Recruiting
    • Peritoneal Malignant Mesothelioma
    • Atezolizumab
    • +8 more
    • Phoenix, Arizona
    • +25 more
    Feb 2, 2023

    Malignant Pleural Mesothelioma Trial in Worldwide (MORAb-009 (Amatuximab), Pemetrexed, Cisplatin)

    Completed
    Has Results
    • Malignant Pleural Mesothelioma
    • MORAb-009 (Amatuximab)
    • +2 more
    • Birmingham, Alabama
    • +27 more
    Aug 24, 2022

    NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Phoenix, Arizona
    • +303 more
    Aug 17, 2022

    Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

    Not yet recruiting
    • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    • Bengbu, Anhui, China
    • +51 more
    Mar 11, 2023

    NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Telisotuzumab Vedotin
    • +4 more
    • (no location specified)
    Oct 17, 2023

    Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)

    Not yet recruiting
    • Pleural Mesothelioma
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Jul 3, 2023

    NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Feb 22, 2023

    EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)

    Active, not recruiting
    • EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
    • Großhansdorf, Germany
    • +17 more
    Jan 12, 2023

    Unresectable Pleural Mesothelioma Trial in Worldwide (Volrustomig, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Unresectable Pleural Mesothelioma
    • Duarte, California
    • +133 more
    Oct 18, 2023

    Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

    Active, not recruiting
    Has Results
    • Non-Small-Cell Lung Carcinoma
    • Pembrolizumab 200 mg
    • +7 more
    • Nagoya, Aichi, Japan
    • +9 more
    Jan 23, 2023

    NSCLC Trial in Gyeonggi-do, Incheon, Seoul (Lazertinib, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Gyeonggi-do, Korea, Republic of
    • +5 more
    Jul 25, 2022

    Non-Squamous NSCLC Trial in Guangzhou (AK112 Injection, Placebo Injection)

    Recruiting
    • Non-Squamous Non-small Cell Lung Cancer
    • AK112 Injection
    • Placebo Injection
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 23, 2022